OnKure Therapeutics, Inc. OKUR
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
OnKure Therapeutics, Inc. (OKUR) is a healthcare company listed in the US with a market value of about $107M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -52%.
About OnKure Therapeutics
OnKure Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 5864% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | — | — |
| Net income | -$60M | -$53M | -$35M | -$52M | -$40M | -$19M |
| Free cash flow | -$52M | -$51M | -$35M | -$48M | -$38M | -$19M |
| EPS (diluted) | $-4.40 | $-15.28 | $-124.41 | $-229.14 | $-236.71 | $-1037.62 |
| Net margin | — | — | — | — | — | — |
| ROIC | -87.7% | -40.9% | — | — | -27.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does OnKure Therapeutics pay a dividend?
Not currently.
Is OnKure Therapeutics a good stock to buy?
We do not give buy or sell advice. OnKure Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.